Skip to content
ES
MARKETS / NASDAQ / NEOG
NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · LARGE CAP

Neogen Corp. NEOG

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$870.4M
▼ 2.7% YoY
$-7.9M
$31.9M
In brief

What this company does

It maintains locations outside of the United States in 28 other countries to provide a direct sales presence. Its Food Safety and Animal Safety segments organize sales efforts by specific markets and geography. The Food Safety segment consists primarily of diagnostic test kits and complementary products sold to food and animal feed producers and processors to help prevent contamination and foodborne illnesses such as pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. Neogen Corporation was formed as a Michigan corporation in June 1981, and operations began in 1982.

Written from the business description in NEOGEN CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 30 July 2026. Every sentence was checked against that document before publication.

Growth
USD 870.4M
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 0.9 · Net income -0.0
0.4B0.8B-0.4B-0.8B200920112013201520172019202120232025
Compound annual growth
+1.9%
+13.2%
+10.5%
+11.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +13.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−1 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -2.5% · Net -0.9%
10%20%-50%-100%200920112013201520172019202120232025
ROE
FY2025 · ROE -0.4%
5%10%-20%-40%200920112013201520172019202120232025
Gross margin46.9%
Operating margin-2.5%
Net margin-0.9%
Return on assets-0.2%
EBITDAUSD 94.7M

Each USD of equity lost 0 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 31.9
25.0M50.0M-40.0M200920112013201520172019202120232025
Net buybacks $M Dividends $M
FY2018 · Dividends — · Net buybacks 3.1
2M2018
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 3.3B
EquityUSD 2.1B
CashUSD 185.5M
Gross debtUSD 793.7M
Net debtUSD 608.2M
Current ratio3.82×

Net debt stands at 29% of equity.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.90.90.90.80.50.50.40.40.40.40.30.30.20.20.20.20.1
Operating income $B−0.0−1.10.10.00.10.10.10.10.10.10.10.10.00.00.00.00.0
EBITDA $B0.1−0.90.20.10.10.10.10.10.10.10.10.10.10.00.00.00.0
Income tax $B−0.0−0.0−0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Net income $B−0.0−1.1−0.0−0.00.00.10.10.10.10.00.00.00.00.00.00.00.0
Free cash flow $B0.0−0.0−0.1−0.00.00.10.10.00.00.00.00.00.00.00.00.00.0
EPS, diluted $−0.04−5.03−0.04−0.120.450.570.560.571.210.860.720.900.760.750.620.960.76
Dividend / sh $·················
Payout %·················
ROE %−0.4−41.9−0.3−1.15.67.88.710.012.210.09.710.210.011.411.012.1·
Shares out B0.220.220.220.220.110.110.110.050.050.050.040.040.040.040.020.02·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Neogen Corp.vsIdexx Laboratories Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesNeogen Corp.vsQuidelOrtho Corp.Same industry: In Vitro & In Vivo Diagnostic SubstancesNeogen Corp.vsLantheus Holdings, Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesNeogen Corp.vsIntellia Therapeutics, Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesNeogen Corp.vsCelldex Therapeutics, Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesNeogen Corp.vsMyriad Genetics Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesNeogen Corp.vsTrinity Biotech PLCSame industry: In Vitro & In Vivo Diagnostic Substances
Provenance
Company facts, as filed
How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onNASDAQ
Incorporated inMichigan
Fiscal year endsMay 31
Data on record since2009

Share this section

Download image